Abstract: A compound capable of specifically binding to pathogen EF-1? but not host EF-1?, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.

Abstract: Recombinant transferrin, non-glycosylated recombinant transferrin, transferrin half-molecules and mutant transferrins having altered metal-binding or other properties are described. The recombinant transferrin molecules are expressed in functional form by stable eukaryotic cell lines such as baby hamster kidney cells transformed with an expression vector encoding the recombinant molecule. The recombinant transferrins can be used in metal chelation therapy to bind and clear excess toxic metals in patients suffering from metal overloads or as tissue culture medium supplements or replacements.

Abstract: An ultrasound imaging and medical instrument guiding apparatus comprises: a first ultrasound probe configured to acquire a first volumetric dataset representing a 3-D image of a first volume; a second ultrasound probe configured to acquire a second volumetric dataset representing a 3-D image of a second volume; a mount to which the first and second probes are mounted, and a medical instrument guide. The first and second probes are located on the mount such that the first and second volumes overlap to form an overlapping volume. The medical instrument guide is positionable relative to the first and second ultrasound probes and is configured to receive and guide a medical instrument along a propagation axis to a target such that the target and the propagation axis intersect the overlapping volume.

Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

Abstract: Methods and apparatus for concentrating particles may be applied, for example, to concentrating DNA, RNA, proteins and the like. Proteins may be pre-treated to facilitate concentration by scodaphoresis. The pre-treatment may comprise, for example, heating or chemical treatment to denature and/or apply a net charge to the protein, binding handle particles to the protein and combinations thereof. High-conductivity samples may be subjected to a conductivity-reduction step to facilitate electrical injection of target particles into scodaphoresis media. The conductivity-reduction step may comprise a buffer exchange process or a salt extraction process, for example. Methods and apparatus can allow two or more different types of target particles to be extracted from the same sample and separately concentrated. These various aspects may be applied individually or in any combination.

Abstract: A reflective display having a plurality of transparent hemi-beads (60), each having a reflective region (80) surrounding a non-reflective region (82). Light absorbing, electrostatically charged ions are dissolved in an electrophoretic medium (20) maintained adjacent the hemi-beads. A voltage applied across the medium moves many ions into an evanescent wave region adjacent the hemi-beads where the ions absorb light, frustrating TIR at the reflective regions. Ions in the evanescent wave region also absorb light which does not undergo TIR and which would otherwise pass through the non-reflective regions. An opposite voltage applied across the medium moves many ions away from the hemi-beads, allowing light to undergo TIR at the reflective regions. The display's brightness can be enhanced by providing a backplane electrode (48) having reflective regions (108; 110, 112) for reflecting back through the hemi-beads light which passes through the non-reflective regions to the backplane electrode.

Abstract: Apparatus, methods, media, signals and data structures for protein sequence analysis are disclosed. A method includes identifying, from among a first group of aligned protein sequences having at least a threshold degree of alignment with a first protein sequence, a second group of at least one of the aligned sequences having at least one insertion or deletion (“indel”) relative to the first protein sequence satisfying a predefined condition. The apparatus may include a processor circuit configured to carry out the method.

Abstract: A method and apparatus for processing ultrasonic image signals is disclosed. The method involves receiving a plurality of input sample values representing reflected sound waves in a ultrasonic system, exponentiating each input sample to produce a plurality of respective exponentiated sample values, conditioning the exponentiated sample values to produce conditioned exponentiated sample values for receipt by an imageformer, and causing the imageformer to produce an image representing the ultrasonic sound waves in response to the conditioned exponentiated sample values.

Abstract: The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (SPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA, and a kit for the detection of EspA-producing E. coli.

Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

Abstract: Longitudinally adjacent plane mirrors (106-114) are pivotally interconnected in a columnar array (56) by non-stretching linkages (120) which constrain movement of the mirrors such that their normal vectors (115) remain parallel. Pivotable couplings (122, 124) in two mirrors permit movement of the mirrors with respect to mutually perpendicular axes (x, y) and prevent movement of the mirrors with respect to a third axis (z). Two actuators (117A, 117B) coupled to one of the pivotable couplings controllably move a selected mirror with respect to the mutually perpendicular axes (x, y). A first frame (116) couples the mirror columns together so that movement of the selected mirror moves all the mirrors in unison. The actuators controllably move the mirrors to orient the normal vectors such that the mirrors specularly reflect incident light in a preselected direction.

Abstract: Particular naturally occurring glycosylated acyl-flavonols, e.g.

Abstract: A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject.

Abstract: The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling,

Abstract: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.

Abstract: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Abstract: Apparatus for dispensing droplets of reagent onto samples includes a probe tip to which droplets of reagent can adhere. The apparatus advances the probe tip toward a sample until a droplet of reagent touches the sample and is pulled off from the probe tip. A sensor detects that the droplet has been pulled off from the probe tip and halts the advance of the probe tip before the probe tip touches the sample. Such apparatus may be used to automatically dispense small volumes of reagent onto fragile samples.

Abstract: Described herein are a method and a reactor for reducing NOx contained in a gaseous emission stream. The method and the reactor both utilize an adsorption region in which NOx is adsorbed by either a catalyst material or a non-catalytic adsorbent material and a reduction region in which the adsorbed NOx is catalytically reduced by a hydrocarbon stream. Concentrations of components that inhibit catalytic NOx reduction, such as water vapour, oxygen, and sulphur dioxide, are lower in the reduction region than in the adsorption region. By adsorbing NOx in the adsorption region of the reactor and reducing NOx in the reduction region of the reactor, the reactor and method described herein allow for the efficient reduction of NOx from the emission stream even when the emission stream has a relatively high concentration of components that can inhibit efficient NOx reduction.

Abstract: CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy.

Abstract: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.